Alembic Pharmaceuticals Limited wins USFDA approval for Venetoclax

Alembic Pharmaceuticals Limited announced final approval from the US Food and Drug Administration (USFDA) on 30 October 2026 for Venetoclax tablets in 10 mg, 50 mg and 100 mg strengths. The approved application is therapeutically equivalent to AbbVie Inc.'s Venclexta, while Alembic said it may be eligible for 180 days of generic-drug exclusivity in a US$158.4 crore US market.

What USFDA approval did Alembic receive for Venetoclax?

Alembic received USFDA final approval for an Abbreviated New Drug Application (ANDA) for Venetoclax tablets in 10 mg, 50 mg and 100 mg strengths. The company disclosed the approval to BSE Limited and the National Stock Exchange of India Ltd. on 30 October 2026.

The approved ANDA is therapeutically equivalent to Venclexta tablets, the reference listed drug (RLD) of AbbVie Inc. The RLD comparison applies to the same three strengths, 10 mg, 50 mg and 100 mg, identified in Alembic's announcement.

Final approval places the Venetoclax application within Alembic's reported 228 final USFDA ANDA approvals, rather than its 20 tentative approvals. The company reported 248 cumulative USFDA ANDA approvals, but did not disclose a product launch date, selling price, sales forecast or expected market share for Venetoclax.

Which patients can use Alembic's approved Venetoclax tablets?

Alembic's Venetoclax tablets are indicated for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The announced product strengths are 10 mg, 50 mg and 100 mg, and the release directs readers to the label for detailed indication and usage information.

Venetoclax is also indicated for certain newly diagnosed acute myeloid leukemia (AML) patients when used with azacitidine, decitabine or low-dose cytarabine. The specified group comprises adults aged 75 years or older, or adults with comorbidities that preclude intensive induction chemotherapy.

The 30 October 2026 release does not provide patient numbers, dosing schedules, treatment duration or a split of the US$158.4 crore market between CLL, SLL and AML. It therefore establishes the labelled treatment settings for the 10 mg, 50 mg and 100 mg tablets without quantifying demand by condition.

Could Alembic obtain 180 days of Venetoclax exclusivity?

Alembic may be eligible for 180 days of generic-drug exclusivity because it was a first ANDA applicant to submit a substantially complete application with a Paragraph IV certification for the three Venetoclax strengths. The company described eligibility as a possibility following final approval, not as an exclusivity award that has already started.

The Paragraph IV certification is the filing mechanism Alembic identified in connection with its first-applicant status. Its statement covers the 10 mg, 50 mg and 100 mg tablets together and does not identify one strength as the basis for the possible 180-day period.

Alembic did not disclose the potential exclusivity start date, whether exclusivity could be shared with another applicant, or any litigation or launch condition affecting availability. The 180-day period is therefore a possible regulatory-commercial feature of the approved ANDA, rather than a disclosed revenue target.

How large is the US Venetoclax market cited by Alembic?

The US market for Venetoclax tablets in 10 mg, 50 mg and 100 mg strengths was estimated at US$158.4 crore for the 12 months ended June 2026, according to IQVIA data cited by Alembic. This is the only market-size figure in the 30 October 2026 announcement.

The US$158.4 crore estimate is a measure of the overall US market, not Alembic revenue. The release does not state Alembic's expected volume, net price, market share, manufacturing capacity or forecast revenue from the approved product.

The cited 12-month period ended in June 2026, whereas Alembic announced final USFDA approval on 30 October 2026. The filing therefore provides a trailing market reference for the three approved strengths but no later IQVIA market update as of the approval announcement.

What does Venetoclax add to Alembic's USFDA approval record?

Alembic reported 248 cumulative USFDA ANDA approvals, comprising 228 final approvals and 20 tentative approvals, in its 30 October 2026 release. The 208-approval difference between the two categories shows that final approvals account for the larger reported portion of its cumulative ANDA record.

Alembic describes itself as a vertically integrated research and development pharmaceutical company that manufactures and markets generic pharmaceutical products globally. The company said its research and manufacturing facilities are approved by regulatory authorities in developed countries, including the USFDA.

In India, Alembic said its branded-generic products are marketed through a field force of more than 5,800. That domestic commercial detail is separate from the US Venetoclax ANDA, for which the release identifies final USFDA approval, Venclexta as the RLD and the US$158.4 crore IQVIA market estimate.

Conclusion

Alembic's final approval creates a USFDA-cleared generic equivalent to Venclexta in 10 mg, 50 mg and 100 mg strengths for the disclosed CLL, SLL and specified AML settings. The product addresses a US market estimated at US$158.4 crore for the 12 months ended June 2026, while Alembic's cumulative ANDA record stood at 248 approvals, including 228 final approvals.

The next development to watch is the possible 180-day generic-drug exclusivity because Alembic said its first substantially complete Paragraph IV ANDA filing may make it eligible. The 30 October 2026 announcement does not set a launch date or exclusivity start date, or disclose product revenue expectations, leaving those matters unresolved.